WebDoctor Encyclopedia

Childhood Genitourinary

Leydig cell tumour of the testis

Leydig cell tumours grow from the testosterone-making cells of the testicle. Most are benign and are found in boys with early puberty or men with breast swelling or infertility, and many can be treated with testis-sparing surgery.

Medically reviewed Last reviewed November 15, 2026

What is a Leydig cell tumour of the testis?

A Leydig cell tumour is a rare growth of the testicle that starts in the Leydig cells, the cells that make the male hormone testosterone. Because these cells produce hormones, the tumour can release extra testosterone or oestrogen, which may cause noticeable body changes.

Leydig cell tumours are the most common sex cord-stromal tumours of the testis, a group of tumours that arise from the supporting and hormone-making tissue rather than from sperm-forming cells. Overall they account for only about 1-3% of testicular tumours. Most testicular cancers are germ cell tumours (seminomas and non-seminomas), which are different diseases.

The tumour has two age peaks: boys aged about 5 to 10, and men aged about 30 to 60. In boys it may cause early puberty. In men it may cause breast enlargement, low sex drive or infertility, although many tumours are now found by chance on an ultrasound scan.

The great majority of Leydig cell tumours, around 9 in 10, are benign. A small proportion, almost always in older men, behave as cancers and spread (Cheville et al., 1998). Small benign-looking tumours can often be removed while keeping the testicle (Bozzini, Ratti and Carmignani, 2017).

1. Key facts at a glance

Feature Details
Type of tumour Sex cord-stromal tumour arising from testosterone-producing cells
How common About 1-3% of testicular tumours
Age Boys 5-10 years and men 30-60 years
Benign or malignant About 90% benign; malignant forms mainly in older men
Hormone effects Early puberty in boys; breast swelling, low libido or infertility in men
Tumour markers (AFP, hCG) Usually normal
Main treatment Testis-sparing surgery or removal of the testicle
Outlook Excellent for benign tumours; poorer when the tumour has spread

2. Benign and malignant Leydig cell tumours

There is no single test that proves a Leydig cell tumour is malignant unless it has already spread. Pathologists look for a group of worrying features.

Feature Benign-looking tumour Features suggesting malignancy
Size Usually under 3 cm Larger, often over 5 cm
Cell division Few mitoses Many mitoses, including abnormal forms
Necrosis Absent Present
Edges Well defined Infiltrating the surrounding testis
Spread into vessels Absent Present
Extension Confined to the testis Into the rete testis, epididymis or covering layers
Cell atypia Mild Marked
Proliferation (Ki-67) Low High

In a study of 30 tumours, those that spread were on average larger (4.7 versus 2.6 cm) and showed far more cell division than those that did not (Cheville et al., 1998). Tumours with several of these features are watched more closely.

How it differs from germ cell testicular cancer

Feature Leydig cell tumour Germ cell tumour (seminoma or non-seminoma)
Cell of origin Hormone-making Leydig cells Sperm-forming germ cells
Frequency Rare About 95% of testicular cancers
Hormone effects Common Uncommon
Blood markers (AFP, hCG) Normal Often raised
Behaviour Mostly benign Malignant
Response to chemotherapy Poor in the rare malignant cases Usually excellent

3. Causes and risk factors

The cause is usually unknown. Several conditions are linked with a higher risk.

Factor Notes
Undescended testicle History of cryptorchidism
Klinefelter syndrome Leydig cell overgrowth is common in this condition
Infertility Small tumours are often found during fertility tests
Hereditary leiomyomatosis and renal cell cancer (HLRCC) Changes in the fumarate hydratase (FH) gene occur in a minority
Hormone imbalance Long-term high levels of the hormone LH may contribute

Gene changes

Some Leydig cell tumours show changes in FH, and childhood tumours may carry activating changes in the LH receptor or GNAS genes. Most cases are not inherited. Genetic counselling may be offered if an FH change is found or if there is a family history of kidney cancer and skin or uterine fibroids.

4. How does it look

On the outside

Many tumours are too small to feel and are found only on ultrasound. When felt, the tumour is a firm, painless lump in the testicle. Hormone effects may be the only visible sign.

Feature Description
Lump Small, firm, often under 2-3 cm
Scrotum Usually looks normal
Breasts Swollen and sometimes tender (gynaecomastia) in men
Boys Signs of early puberty: pubic hair, deeper voice, penile growth, growth spurt

On scans

Ultrasound typically shows a small, well-defined, dark (hypoechoic) nodule with blood flow around its edge. Contrast-enhanced ultrasound and MRI can help to distinguish a Leydig cell tumour from a germ cell cancer, because Leydig tumours tend to light up strongly and quickly. A CT scan of the chest, abdomen and pelvis is used if the tumour has malignant features.

Under the microscope

Feature Description
Cells Large polygonal cells with plentiful pink cytoplasm
Reinke crystals Rod-shaped crystals seen in a proportion of cases
Pigment Brownish lipochrome pigment in some cells
Arrangement Sheets, nests or cords
Stains Inhibin, calretinin, SF-1 and Melan-A positive

5. Symptoms

Common symptoms

  • A painless lump or swelling in one testicle
  • Breast enlargement or tenderness (gynaecomastia) in adult men
  • Reduced sex drive or erection problems
  • Difficulty fathering children
  • No symptoms at all, with the tumour found on a scan

Less common symptoms

Symptom What it may mean
Early puberty in a boy Excess testosterone
Testicular ache Larger tumour
Back pain Rarely, spread to lymph nodes at the back of the abdomen
Cough or breathlessness Rarely, spread to the lungs
Weight loss Advanced malignant tumour

When to seek medical advice

See a doctor about any new lump, swelling or change in a testicle, and about breast swelling in a man or signs of puberty in a young child. Most testicular lumps are not Leydig cell tumours, but all need prompt assessment.

6. Diagnosis

Test Purpose
Examination Checks the testicles, breasts and signs of puberty
Scrotal ultrasound Main test for finding and measuring the tumour
Tumour markers (AFP, hCG, LDH) Usually normal; helps rule out germ cell cancer
Hormone tests Testosterone, oestradiol, LH and FSH
Semen analysis Checks fertility, and allows sperm banking before surgery
Contrast ultrasound or MRI Characterises small or uncertain lesions
CT scan Staging if malignancy is suspected
Pathology Confirms the diagnosis after surgery

Leydig cell tumours in children

In boys, the tumour usually shows itself through signs of early puberty, such as rapid growth, pubic hair, acne, a deeper voice and enlargement of the penis, sometimes before any lump is felt. Doctors check hormone levels and bone age, and rule out other causes of early puberty such as adrenal gland conditions. Childhood tumours are almost always benign, and testis-sparing surgery is usually the preferred operation (Zu’bi et al., 2019). Some boys continue to need monitoring by a paediatric endocrinologist, because puberty can carry on early even after the tumour has been removed.

Staging

Stage What it means
Stage I Tumour confined to the testis
Stage II Spread to lymph nodes at the back of the abdomen
Stage III Spread to distant organs such as the lungs, liver or bones

7. Treatment

Treatment is planned by a urology or testicular cancer team, together with an endocrinologist and, for boys, a paediatric surgeon.

Surgery

Option Who it suits Notes
Testis-sparing surgery Small tumours with no worrying features Removes only the tumour, often guided by ultrasound and checked with frozen section
Radical inguinal orchidectomy Larger tumours, uncertain diagnosis or malignant features Removes the whole testicle through the groin
Retroperitoneal lymph node dissection (RPLND) Selected malignant tumours Removes lymph nodes at the back of the abdomen

A review of 247 patients found that none of the 102 men treated with testis-sparing surgery developed spread of the tumour during follow-up (Bozzini, Ratti and Carmignani, 2017). Testis-sparing surgery is also widely used in children, with good results even when margins were not completely clear (Zu’bi et al., 2019).

Treatment of malignant tumours

Malignant Leydig cell tumours respond poorly to chemotherapy and radiotherapy. Surgery is the main treatment.

Option Notes
RPLND May help in early malignant disease; outcomes are poorer once nodes are involved (Hendry et al., 2015)
Mitotane A drug that blocks hormone production; used occasionally
Chemotherapy Limited benefit; used mainly for symptom control
Clinical trials Recommended where available

Side effects

Treatment Possible side effects
Testis-sparing surgery Bruising, swelling, small risk of later removal of the testicle
Orchidectomy Scrotal swelling, change in appearance (a prosthesis can be offered)
Loss of hormone production Low testosterone, especially if the other testicle is weak; testosterone replacement can help
RPLND Abdominal recovery, risk of problems with ejaculation

What treatment involves day to day

Stage What to expect
Testis-sparing surgery or orchidectomy Usually a day case or one night in hospital
Recovery Light activity within a week; avoid heavy lifting for 2-4 weeks
Hormone review Blood tests over the following weeks
RPLND, if needed About a week in hospital and several weeks of recovery

8. Outlook (prognosis)

Situation Usual outcome
Benign tumour, completely removed Cured in nearly all cases
Tumour in a child Excellent; malignant behaviour is almost unheard of
Tumour with several worrying features Higher risk of spread; closer follow-up
Tumour that has spread Poor; often fatal within a few years

Hormone-related changes such as breast swelling often improve after surgery, though they may not disappear completely. Early puberty changes in boys may only partly reverse.

9. Follow-up

Follow-up Purpose
Scrotal ultrasound Checks the remaining testicle and the operated testis
Hormone tests Monitors testosterone and oestrogen
CT scans For tumours with worrying features
Growth and puberty monitoring For boys
Duration Often several years; longer for high-risk tumours

10. Living with a Leydig cell tumour

  • Examine your testicles once a month, after a warm bath or shower, and report any change
  • Discuss sperm banking before surgery if fertility is a concern
  • Ask about testosterone replacement if you have symptoms of low testosterone
  • Ask about a testicular prosthesis if the testicle is removed
  • Keep follow-up appointments, even when you feel well, because late spread is possible with high-risk tumours
  • Tell your doctor about breast changes that persist or return after surgery
  • Seek support from testicular cancer charities, which also help men with rarer tumours

11. Frequently asked questions

Question Answer
Is a Leydig cell tumour cancer? Usually not; about 9 in 10 are benign
Do I have to lose my testicle? Not always; small tumours can often be removed alone
Will my breasts go back to normal? Often they improve, but not always completely
Will I be able to have children? Many men can; sperm banking may be offered beforehand
Do I need chemotherapy? Almost never
Is it the same as testicular cancer? It is a different, much rarer tumour from the common germ cell cancers
Can boys get it? Yes, and in children it is almost always benign
Can it come back in the other testicle? Rarely; tumours in both testicles occur in only a small minority
Will my testosterone level drop? Usually not if the other testicle works normally; levels are checked after surgery

12. Questions to ask your care team

  • Does my tumour have any features of malignancy?
  • Is testis-sparing surgery possible for me?
  • Should I bank sperm before surgery?
  • Will I need hormone treatment afterwards?
  • What scans will I need, and for how long?
  • Should I have genetic testing?

Resources

  1. Bozzini, G., Ratti, D. and Carmignani, L. (2017) ‘Treatment of Leydig cell tumours of the testis: can testis-sparing surgery replace radical orchidectomy? Results of a systematic review’, Actas Urologicas Espanolas, 41(3), pp. 146-154.
  2. Cheville, J.C. et al. (1998) ‘Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors’, American Journal of Surgical Pathology, 22(11), pp. 1361-1367.
  3. Hendry, J. et al. (2015) ‘Retroperitoneal lymph node dissection (RPLND) for malignant phenotype Leydig cell tumours of the testis: a 10-year experience’, SpringerPlus, 4, 20.
  4. Zu’bi, F. et al. (2019) ‘Testis-sparing surgery for pediatric Leydig cell tumors: evidence of favorable outcomes irrespective of surgical margins’, Urology, 134, pp. 203-208.
  5. National Cancer Institute (2026) Testicular Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/testicular/hp/testicular-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.